安旭生物发布2025年度业绩快报，盈利0.734亿元

Core Viewpoint - The company, Anxu Biotech, is set to release its 2025 annual report, revealing a significant decline in net profit by 61.84% year-on-year, amounting to 73.38 million yuan [1]. Financial Performance Summary - The company reported an operating revenue of 453.58 million yuan, a decrease of 16.11% compared to the previous year [2]. - The net profit attributable to the parent company was 73.38 million yuan, down 61.84% year-on-year [2]. - The net profit attributable to the parent company, excluding non-recurring gains and losses, was 15.37 million yuan, reflecting a decline of 59.44% [2]. - Total assets at the end of the reporting period were 5.61 billion yuan, a decrease of 2.72% from the end of the previous year [2]. - The equity attributable to the parent company was 5.17 billion yuan, down 0.64% from the end of the previous year [2]. Operational and Strategic Insights - The company aims for stable development in its core business, integrating quality technology resources and increasing strategic investments in new technology platforms [2]. - Efforts to enhance operational efficiency and cost control through lean management have shown significant results [2]. - The company is expanding its international presence, with positive progress in overseas market development, although this has led to increased sales expenses [2]. Factors Affecting Performance - The decline in net profit is attributed to multiple external factors, including increased tariffs imposed by the U.S. government, which reduced orders in certain markets and raised operating costs [3][4]. - Additional factors contributing to the profit decline include exchange rate fluctuations, reduced interest income, and depreciation expenses [3][4]. Business Focus - Anxu Biotech specializes in the research, development, production, and sales of POCT (Point of Care Testing) reagents and instruments [5].